WallStreetZenWallStreetZen

NASDAQ: ONCT
Oncternal Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ONCT past revenue growth

How has ONCT's revenue growth performed historically?
Company
-47.32%
Industry
145.73%
Market
17.2%
ONCT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ONCT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ONCT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ONCT earnings and revenue history

Current Revenue
$785.0k
Current Earnings
-$39.5M
Current Profit Margin
-5,029.2%

ONCT Return on Equity

Current Company
-95.9%
Current Industry
-63.5%
Current Market
188%
ONCT's Return on Equity (-95.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ONCT announces earnings.

ONCT Return on Assets

Current Company
-83.6%
Current Industry
2.9%
ONCT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ONCT Return on Capital Employed

Current Company
-125.21%
Current Industry
19.5%
ONCT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ONCT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ONCT$785.00k-$39.31M-$39.48M-20.81%N/A
LPCN-$2.85M-$16.32M-$16.35MN/AN/A
UBX$0.00-$36.23M-$39.86M-100.00%N/A
SLGL$1.55M-$26.90M-$27.24M+64.50%N/A
SNSE$0.00-$31.25M-$34.10MN/AN/A
View Top Biotech Stocks

ONCT earnings dates

Next earnings date
May 2, 2024

Oncternal Therapeutics Earnings & Revenue FAQ

What were ONCT's earnings last quarter?

On Invalid Date, Oncternal Therapeutics (NASDAQ: ONCT) reported Q4 2023 earnings per share (EPS) of -$3.03, up 24.25% year over year. Total Oncternal Therapeutics earnings for the quarter were -$9.16 million. In the same quarter last year, Oncternal Therapeutics's earnings per share (EPS) was -$4.00.

If you're new to stock investing, here's how to buy Oncternal Therapeutics stock.

What was ONCT's earnings growth in the past year?

As of Q2 2024, Oncternal Therapeutics's earnings has grown year over year. Oncternal Therapeutics's earnings in the past year totalled -$39.48 million.

What is ONCT's earnings date?

Oncternal Therapeutics's earnings date is Invalid Date. Add ONCT to your watchlist to be reminded of ONCT's next earnings announcement.

What was ONCT's revenue last quarter?

On Invalid Date, Oncternal Therapeutics (NASDAQ: ONCT) reported Q4 2023 revenue of $297.00 thousand up 73.68% year over year. In the same quarter last year, Oncternal Therapeutics's revenue was $171.00 thousand.

What was ONCT's revenue growth in the past year?

As of Q2 2024, Oncternal Therapeutics's revenue has grown -47.32% year over year. This is 193.05 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Oncternal Therapeutics's revenue in the past year totalled $785.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.